Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease
Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease
复制标题
DOI：
10.1111/j.1365-2141.2006.06321.x
复制
发表时间：
2006-11-01
影响因子：
6.5
通讯作者：
Feugier, Pierre
中科院分区：
文献类型：
--
作者：
Bordigoni, Pierre;Dimicoli, Sophie;Feugier, Pierre
在一项 II 期研究中，达克珠单抗作为单一二线药物给予 62 名患有类固醇难治性急性移植物抗宿主病 (aGVHD) 的患者。 68.8% 的患者的 aGVHD 完全缓解。这种反应率与较少数量的受累器官和较小的皮肤受累程度显着相关。 4 年无事件生存率 (EFS) 为 54.6%。 ≥ III 级 aGVHD、基线时受累器官≥ 2 个以及患者年龄 > 18 岁与较低的 EFS 独立相关。达珠单抗可能是治疗 aGVHD 的合适替代疗法，特别是当仅限于皮肤或胃肠道时。
In a phase II study, daclizumab was given as single second-line agent to 62 patients with steroid-refractory acute graft-versus-host disease (aGVHD). Complete resolution of aGVHD was achieved in 68.8% of patients. This response rate was significantly associated with a lower number of involved organs and smaller extent of skin involvement. The 4-year event-free survival (EFS) was 54.6%. Grade >= III aGVHD, >= 2 involved organs at baseline and patient age > 18 years were independently associated with lower EFS. Daclizumab could be a suitable alternative treatment for aGVHD, particularly when limited to the skin or gastrointestinal tract.